AbbVie (NYSE: ABBV) announced the publication of results from the Phase 3 TEMPLE study in The Lancet Neurology. The randomized, double-blind, head-to-head study evaluated the tolerability, safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results